Search

Your search keyword '"Anne Jolivot"' showing total 33 results
Start Over Author "Anne Jolivot"
33 results on '"Anne Jolivot"'

1. Using ELEFIGHT® QR Codes for Quick Access to Information on Influenza Burden and Prevention: A Pilot Study in Lyon University Hospital

Author

Nagham Khanafer, Sylvain Oudot, Catherine Planckaert, Nathalie Paquin, Camille Mena, Nadège Trehet Mandel, Roland Chapurlat, Catherine Lombard, Géraldine Martin-Gaujard, Laurent Juillard, Christelle Elias, Audrey Janoly-Dumenil, Anne Jolivot, Meriem Benazzouz, Margot Maligeay, Marie-Pierre Ayala, Diana Ismail, and Philippe Vanhems

Subjects
influenza, flu, VCR, QR code, hospital, prevention, Medicine
Abstract

(1) Background: The Vaccine Coverage Rate of influenza remains low and omnichannel efforts are required to improve it. The objective was to evaluate the feasibility and outcomes of a QR Code nudging system in outpatient departments. (2) Methods: The study was performed in 6 departments ensuring ambulatory activities in a French university Hospital between November and December 2021. By scanning QR codes, users accessed anonymously to the ELEFIGHT® web app, which provides medical information on influenza and invites them to initiate a discussion about influenza prevention with their physicians during the consultation. (3) Results: 351 people made 529 scans with an average reading time of 1 min and 4 s and a conversion rate of 32%, i.e., people willing to engage in a discussion. (4) Conclusions: The study suggests that direct access to medical information through QR codes in hospitals might help nudge people to raise their awareness and trigger their action on influenza prevention.

Published
2022
Full Text
View/download PDF

2. Prediction Tool to Estimate Potassium Diet in Chronic Kidney Disease Patients Developed Using a Machine Learning Tool: The UniverSel Study

Author

Maelys Granal, Lydia Slimani, Nans Florens, Florence Sens, Caroline Pelletier, Romain Pszczolinski, Catherine Casiez, Emilie Kalbacher, Anne Jolivot, Laurence Dubourg, Sandrine Lemoine, Celine Pasian, Michel Ducher, and Jean Pierre Fauvel

Subjects
potassium diet, prediction tool, Bayesian network, chronic kidney disease, Epidemiology, Nutrition. Foods and food supply, TX341-641
Abstract

There is a need for a reliable and validated method to estimate dietary potassium intake in chronic kidney disease (CKD) patients to improve prevention of cardiovascular complications. This study aimed to develop a clinical tool to estimate potassium intake using 24-h urinary potassium excretion as a surrogate of dietary potassium intake in this high-risk population. Data of 375 adult CKD-patients routinely collecting their 24-h urine were included to develop a prediction tool to estimate potassium diet. The prediction tool was built from a random sample of 80% of patients and validated on the remaining 20%. The accuracy of the prediction tool to classify potassium diet in the three classes of potassium excretion was 74%. Surprisingly, the variables related to potassium consumption were more related to clinical characteristics and renal pathology than to the potassium content of the ingested food. Artificial intelligence allowed to develop an easy-to-use tool for estimating patients’ diets in clinical practice. After external validation, this tool could be extended to all CKD-patients for a better clinical and therapeutic management for the prevention of cardiovascular complications.

Published
2022
Full Text
View/download PDF

3. Patients’ outcome with polycystic kidney disease firstly treated with peritoneal dialysis. Experience of our home dialysis unit since 1997.

Author

jean-michel Poux, Carlos Cardozo, Laville Maurice, Anne Jolivot, and Jean-Pierre Fauvel

Subjects
peritoneal dialysis, peritonitis, renal transplantation, polycystic kidney disease, Internal medicine, RC31-1245
Abstract

We extracted data from the French Speaking Registry of Peritoneal Dialysis and retrospectively studied peritonitis and the outcome of 30 patients with polycystic kidney disease firstly treated with peritoneal dialysis within our dialysis unit since 1997. There were 15 men and 15 women with a mean age of 54 years. Eighty-five per-cent of the patients had hepatic impairment. Ten patients did not suffer from comorbidities. Charlson comorbidity index was greater than or equal to 4 in five patients. Most of the patients was treated with automated peritoneal dialysis during the night. Only one patient was not autonomous with peritoneal dialysis. The whole medical monitoring lasted 836 months, representing an average of 28 months per patient. Eleven patients had a total of 24 peritonitis, 9 with gram negative bacillus. The incidence of peritonitis was one episode every 35 months-patient. Peritonitis was responsible for sudden admission in hemodialysis unit in two cases and death in one case. Fifteen patients (50%) benefited from renal transplantation. Only one patient had to undergo nephrectomy prior to renal transplantation. Seven patients were admitted to hemodialysis unit (the median duration time on peritoneal dialysis was 36 months). Four patients died. Four patients are currently treated with peritoneal dialysis. In conclusion, this retrospective study points out that peritoneal dialysis, especially automated peritoneal dialysis, is a good option for patients with polycystic kidney disease necessitating dialysis.

Published
2021
Full Text
View/download PDF

4. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial

Author

Djamal Djeddi, Julien Hogan, Aubriana Perez, Anne-Laure Sellier-Leclerc, Isabelle Vrillon, Francoise Broux, Francois Nobili, Jerome Harambat, Lucie Bessenay, V Audard, Camille Faudeux, Denis Morin, Christine Pietrement, Stephanie Tellier, Philippe Eckart, Annie Lahoche, G Roussey-Kesler, Tim Ulinski, Olivia Boyer, Emmanuelle Plaisier, Sylvie Cloarec, Anne Jolivot, Vincent Guigonis, Sophie Guilmin-Crepon, Veronique Baudouin, Claire Dossier, and Georges Deschênes

Subjects
Medicine
Abstract

Introduction Guidelines for the treatment of steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS) are lacking. Given the substantial impact of SDNS/FRNS on quality of life, strategies aiming to provide long-term remission while minimising treatment side effects are needed. Several studies confirm that rituximab is effective in preventing early relapses in SDNS/FRNS; however, the long-term relapse rate remains high (~70% at 2 years). This trial will assess the association of intravenous immunoglobulins (IVIgs) to rituximab in patients with SDNS/FRNS and inform clinicians on whether IVIg’s immunomodulatory properties can alter the course of the disease and reduce the use of immunosuppressive drugs and their side effects.Methods and analysis We conduct an open-label multicentre, randomised, parallel group in a 1:1 ratio, controlled, superiority trial to assess the safety and efficacy of a single infusion of rituximab followed by IVIg compared with rituximab alone in childhood-onset FRNS/SDNS. The primary outcome is the occurrence of first relapse within 24 months. Patients are allocated to receive either rituximab alone (375 mg/m²) or rituximab followed by IVIg, which includes an initial Ig dose of 2 g/kg, followed by 1.5 g/kg injections once a month for the following 5 months (maximum dose: 100 g).Ethics and dissemination The study has been approved by the ethics committee (Comité de Protection des Personnes) of Ouest I and authorised by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé). Results of the primary study and the secondary aims will be disseminated through peer-reviewed publications.Trial registration number NCT03560011.

Published
2020
Full Text
View/download PDF

5. Using ELEFIGHT

Author

Nagham, Khanafer, Sylvain, Oudot, Catherine, Planckaert, Nathalie, Paquin, Camille, Mena, Nadège Trehet, Mandel, Roland, Chapurlat, Catherine, Lombard, Géraldine, Martin-Gaujard, Laurent, Juillard, Christelle, Elias, Audrey, Janoly-Dumenil, Anne, Jolivot, Meriem, Benazzouz, Margot, Maligeay, Marie-Pierre, Ayala, Diana, Ismail, and Philippe, Vanhems

Abstract

(1) Background: The Vaccine Coverage Rate of influenza remains low and omnichannel efforts are required to improve it. The objective was to evaluate the feasibility and outcomes of a QR Code nudging system in outpatient departments. (2) Methods: The study was performed in 6 departments ensuring ambulatory activities in a French university Hospital between November and December 2021. By scanning QR codes, users accessed anonymously to the ELEFIGHT

Published
2022

6. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

Author

Cécile Couchoud, Florian Bayer, Carole Ayav, Clémence Béchade, Philippe Brunet, François Chantrel, Luc Frimat, Roula Galland, Maryvonne Hourmant, Emmanuelle Laurain, Thierry Lobbedez, Lucile Mercadal, Olivier Moranne, Abdelhamid Abbassi, Alain Debure, Abdallah Guerraoui, Abdelatif Benmoussa, Abdelaziz Hamani, Abdelaziz Ziane, Abdelhamid Nefti, Abdelkader Hadj, Abderrahim El Amari, Abderrahmane Ghazali, Abo Bakr Abd El Fatah Mohamed, Achour Laradi, Adel Ben Ahmed, Adel Sahar, Adele Pillet, Adeline Lacraz, Adnan Moinat, Afshin Massoumi, Agathe Pardon, Agnes Caillette Beaudoin, Agnes Chapelet Debout, Agnes Mariot, Ahmed Rachi, Aida Afiani, Aime Remy Boula, Al Jalaby, Alain Cremault, Alain Fournier, Alain Jeanson, Alain Lyon, Alain Nony, Alain Robert, Alain Slingeneyer, Alanor Agnes Labatide, Albane Brodin Sartorius, Albert Bensman, Albert Fournier, Alex Ranlin, Alex Vido Sandor, Alexandra Colombo, Alexandra Duhem, Alexandra Stancu, Alexandre Dufay, Alexandre Dumoulin, Alexandre Ebel, Alexandre Klein, Alexandre Martin, Alexandre Mouneimne, Alexandre Seidowsky, Alfio De Martin, Alfredo Zannier, Ali Aizel, Ali Hafi, Ali Zineddine Diddaoui, Alim Heyani, Alina Mocanu, Alina Preda, Aline Hafi, Aline Talaszka, Alyette Duquesne, Amar Amaouche, Amel Ghemmour, Amelie Simon, Amina Skalli, Amine Boukadida, Amr Ekhlas Ragab Eid, Ana Fedorca, Anabelle Baillet, Anais Poyet, Ancuta Bouffandeau Giorgita, Anderson Ratsimbazafy, Andre Pruna, Angel Argiles, Angelo Testa, Ann Karolien Vandooren, Anne Jolivot, Anne Kolko Labadens, Anne Lataste, Anne Maisin, Anne Paris, Anne Sechet, Anne Wuillai, Anne Elisabeth Heng, Anne Gaelle Josse, Anne Helene Querard, Anne Helene Reboux, Anne Laure Adra, Anne Laure Faller, Anne Laure Leclerc, Anne Laure Poitou, Annie Lahoche Manucci, Antoine Jacquet, Antoine Pommereau, Antoine Thierry, Arezki Adem, Arielle Chapelet, Arnaud Del Bello, Arnaud Delezire, Arnaud Garnier, Arnaud Guerard, Arnaud Klisnick, Arnaud Lionet, Arnaud Roccabianca, Arnaud Stolz, Arthur Capdeville, Asma Allal, Assem Alrifai, Assetou Diarrassouba, Assia Djema, Assia Ferhat Carre, Astrid Godron Dubrasquet, Atman Haddj Elmrabet, Audrey Jegado, Aurelia Bertholet Thomas, Aurelie Davourie Salandre, Aurelie Pajot, Aurelien Lorthioir, Aurelien Tiple, Aurore Sury, Ayman Abokasem, Ayman Sarraj, Bachir Henaoui, Baher Chaghouri, Bassem Wehbe, Beatrice Ball, Beatrice Viron, Belkassem Issad, Benedicte Hodemon Corne, Benedicte Janbon, Benjamin Deroure, Benjamin Savenkoff, Benoit Jonon, Benoit Vendrely, Benyakoub Djelaleddine, Bernard Ohry, Bernard Painchart, Bernard Strullu, Bernard Temperville, Bertin Ebikili, Bertrand Hacq, Bertrand Morel, Bilal Aoun, Blanca Muniz, Bouchra Chlih, Brahim Amara, Brice Mayor, Brigitte Gilson, Brigitte Llanas, Brigitte Zins, Bruno Bourgeon, Bruno Coevoet, Bruno Guery, Bruno Legallicier, Bruno Paris, Bruno Ranchin, Bruno Seigneuric, Camelia Ghiciuc Dita, Camelia Prelipcean, Carine Achard Hottelart, Carine Diet, Carlos Frangie, Carlos Vela, Carmina Muresan, Carole Deprele, Caroline Araujo, Caroline Bidault, Caroline Creput, Caroline Delclaux, Caroline Du Halgouet, Caroline Favennec, Caroline Freguin, Caroline Gourraud Vercel, Caroline Mesguen, Caroline Ndomo Obama, Caroline Poitou, Caroline Preissig Dirhold, Caroline Roubiou, Catherine Albert, Catherine Bessin, Catherine De Marion Gaja, Catherine Godart, Catherine Lasseur, Catherine Leocardi, Catherine Lumbroso, Catherine Melander, Catherine Michel, Catherine Quere Maurouard, Catherine Rouannet, Catherine Taddei, Cathy Verove, Cecile Guiraud, Cecile Tafelin, Cecile Turc Baron, Cedric Formet, Cedric Pinier, Celia Lessore De Ste Foy, Celine Granolleras, Chaouki Bennini, Charles Cartou, Charles Chazot, Charlotte Jouzel, Cherif Badid, Christa Roubicek, Christel Viaud, Christelle Verrier, Christian Chuet, Christian Combe, Christian Dabot, Christian Duvic, Christian Emond, Christian Lagarde, Christian Lamotte, Christian Pain, Christiane Mousson, Christie Lorriaux, Christine Beauchamp, Christine Fumeron, Christine Le Gurun, Christine Leroy, Christine Pietrement, Christine Richer, Christophe Bouaka, Christophe Charasse, Christophe Goupy, Christophe Ridel, Cindy Castrale, Cindy Detourne, Clair Francois, Claire Presne, Claire Trivin, Clarissa Von Kotze, Claude Bernard, Claude Bonniol, Claude Desvergnes, Claude Raharivelina, Claudia Nistor, Claudine Gueret, Claudine Lloret, Claudine Saltiel, Clelia Rosati, Clementine Rabate, Corina Stanescu, Corinne Ferrandini, Corinne Guibergia, Corinne Lemoine, Corinne Passeron, Cynthia Kahil, Cyril Garrouste, Cyril Vo Van, Cyrille Jolimoy, Dalila Kesraoui, Damien Jolly, Damien Thibaudin, Dan Teboulle, Daniel Daubresse, Daniel Louvet, Daniel Rasamimanantsoa, Daniel Toledano, Daniela Babici, Daniela David, Daniela Dincu, Danielle Bruno, Delia May, Delphine Haussaire, Delphine Henriet Viprey, Denis Bugnon, Denis Fouque, Denis Morin, Derradji Nour, Diab Mohamed Mahmoud, Diana Istrati Cristescu, Didier Aguilera, Didier Coste, Didier Hamel, Didier Le Chapois, Didier Testou, Dilaver Erbilgin, Djamal Dahmane, Doan Bui Quang, Dominique Bertrand, Dominique Besnier, Dominique Blanchier, Dominique Briffa, Dominique Caux, Dominique Durand, Dominique Fleury, Dominique Guerrot, Dominique Hestin, Dominique Jaubert, Dominique Joly, Dominique Lombart, Dominique Pagniez, Dominique Pierre, Dominique Schohn, Donatien Ikonga, Dorina Visanica, Dorothee Bazin, Edouard Boury, Edouard Maksour, Ekoue Agbonon, Elarbi Harrami, Elena Marcu, Elena Tudorache, Elisabeth Caniot, Elisabeth Semjen, Elisabeth Tomkiewicz, Elise Scheidt, Elke Gaboriau, Elodie Lamouroux, Elsa Guiard, Elsa Martin Passos, Emerson Nsembani, Emilie Fache, Emilie Kalbacher, Emilie Pambrun, Emilie Pincon, Emma Allain Launay, Emmanuel Baron, Emmanuel Dupuis, Emmanuel Villar, Emmanuelle Charlin, Emmanuelle Hecquet, Emmanuelle Kohler, Emmanuelle Rosier, Enrique Figueroa, Eric Azoulay, Eric Canivet, Eric Daugas, Eric Gauthier, Eric Laruelle, Eric Le Guen, Eric Legrand, Eric Moumas, Eric Postec, Eric Prinz, Eric Renaudineau, Estelle Desport, Estelle Ricard Sutra, Etienne Berard, Etienne Ged, Etienne Robin, Eve Vilaine, Evelyne Bargas, Evelyne Mac Namara, François Combarnous, Fatima Yazbeck, Fabien Gerard, Fabien Metivier, Fabien Parazols, Fabien Soulis, Fabrice Garnier, Fadhila Pech Messaoudene, Fadi Haidar, Fanny Boullenger, Fanny Lepeytre, Fanny Leroy, Fares Frejate, Farid Bellahsene, Farid Bellhasene, Farid Saidani, Fatouma Toure, Faycal Kriaa, Fazia Nemmar, Fernando Vetromile, Florence Chalmin, Florence Lucats, Florence Sens, Florence Villemain, Florent Plasse, Fouad Lebhour, Francis Schillinger, Franck Berge, Franck Bourdon, Franck Bridoux, Franck Reynaud, Francois Babinet, Francois Basse, Francois Chantrel, Francois Clair, Francois Coulomb, Francois De Cornelissen, Francois Glowacki, Francois Marchal, Francois Maurice, Francois Nobili, Francois Pourreau, Francois Provot, Francois Roux Amani, Francoise Broux, Francoise Bulte, Francoise Heibel, Francoise Leonetti, Francoise Moussion Schott, Frank Le Roy, Frederic Besson, Frederic Lavainne, Frederic Tollis, Frederique Bocquentin, Frederique Meeus, Frederique Vecina, Friederike Von Ey, Gabriel Balit, Gabriel Choukroun, Gabriel Gruget, Gabriel Huchard, Gabriella Golea, Gabrielle Duneau, Gaelle Lefrancois, Gaelle Pelle, Gaetan Lebrun, Genevieve Dumont, Georges Brillet, Georges Deschenes, Georges Mourad, Georges Stamatakis, Geraldine Cazajous, Geraldine D'ythurbide, Geraldine Robitaille Wiart, Gerard Cardon, Gerard Champion, Gerard Deschodt, Gerard Mangenot, Gerard Motte, Gerard Schortgen, Ghada Boulahia, Ghassan Maakaroun, Ghylene Bourdat Michel, Gilbert Zanetta, Gilles Hufnagel, Gilles Messier, Giorgina Piccoli, Gregoire Couvrat Desvergnes, Guillaume Bobrie, Guillaume Bonnard, Guillaume Clement, Guillaume Jean, Guillaume Queffeulou, Guillaume Seret, Guillaume Vernin, Guy Delavaud, Guy Lambrey, Guy Rostoker, Gwenaelle Poussard, Gwenaelle Roussey Kesler, H. Leon, Habib Aboubekr, Hacene Boulechfar, Hacene Sekhri, Hadia Hebibi, Hadjira Benalia, Hafed Fessi, Hafsabhai Atchia, Haiat Bittar, Hakim Maiza, Hakim Mazouz, Hamid El Ali, Hammouche Bougrida, Hans Van Der Pijl, Hassan Lokmane, Hassane Izzedine, Hassen Adda, Helene De Preneuf, Helene Leray, Helene Philippot, Henri Boulanger, Henri Merault, Henri Renaud, Herve Bonarek, Herve Maheut, Hilaire Nzeyimana, Hocine Mehama, Hocine Zaidi, Hugo Weclawiak, Hugues Flodrops, Huseyin Karaaslan, Ibrahim Haskour, Ihssen Belhadj, Imad Almoubarak, Imad Haddad, Ines Castellano, Ines Ferrandiz, Ioana Daniliuc, Ioana Darie, Ioana Enache, Ionut Prunescu, Irenee Djiconkpode, Irina Shahapuni, Isabelle Bouchoule, Isabelle Devriendt, Isabelle Kazes, Isabelle Kolb, Isabelle Landru, Isabelle Poli, Isabelle Rey, Isabelle Segalen, Isabelle Selcer, Isabelle Vernier, Isabelle Vrillon, Ismahane Guenifi, J. Dominique Gheerbrandt, Jacky Potier, Jacques Becart, Jacques Cledes, Jacques Ducros, Jacques Duvic, Jacques Fourcade, Jacques Gaultier, Jacques Jurine, Jacques Lebleu, Jacques Ollier, Jacques Ibsen Charles, Jamal Yazji, Janette Mansour, Jean Arnautou, Jean Brocard, Jean Carolfi, Jean Montoriol, Jean Baptiste Gouin, Jean Bernard Palcoux, Jean Christophe Bendini, Jean Claude Aldigier, Jean Claude Alphonse, Jean Daniel Delbet, Jean Francois Bonne, Jean Francois Cantin, Jean Francois De Fremont, Jean Francois Dessassis, Jean Francois Subra, Jean Francois Valentin, Jean Francois Verdier, Jean Jacques Dion, Jean Jacques Haultier, Jean Jacques Montseny, Jean Louis Bacri, Jean Louis Bouchet, Jean Luc Mahe, Jean Marc Chalopin, Jean Marc Gabriel, Jean Marc Hurot, Jean Marc Lanau, Jean Marie Batho, Jean Marie Coulibaly, Jean Michel Hardin, Jean Michel Marc, Jean Michel Poux, Jean Michel Rebibou, Jean Michel Tivollier, Jean Noel Ottavioli, Jean Paul Faucon, Jean Paul Imiela, Jean Paul Jaulin, Jean Paul Masselot, Jean Paul Ortiz, Jean Philippe Bourdenx, Jean Philippe Devaux, Jean Philippe Hammelin, Jean Pierre Rivory, Jean Pierre Wauquier, Jean Rene Larue, Jean Rene Mondain, Jean Sebastien Borde, Jean Simon Virot, Jean Yves Bosc, Jedjiga Achiche, Jennifer Parasote, Jeremie Diolez, Jerome Harambat, Jerome Potier, Jerome Sampol, Jihad Mustel, Jean Jacques Lefevre, Jocelyne Maurizi, Joel Gamberoni, Joelle Claudeon, Joelle Terzic, Joffrey Rogol, Johnny Sayegh, Jorge Cardozo, Jose Brasseur, Jose Guiserix, Joseph Barsumau, Julie Albaret, Julie Beaume, Julie Sohier Attias, Julien Dehay, Julien Hogan, Julien Journet, Julien Ott, Juliette Baleynaud, Justine Bacchetta, Justine Faucher, Kamel Yousfi, Karim Dardim, Karine Clabault, Karine Moreau, Kedna Thomas, Khaled Sirajedine, Khalil Chedid, Khalil El Kaeoui, Khalil El Karoui, Khedidja Bouachi, Kheira Hue, Khuzama El Nasser, Kodso Akposso, Kristian Kunz, Krzysztof Bijak, Lilia Kihal, L. Rasoloarijaona, Laid Harbouche, Larbi Bencheikh, Larbie Lamriben, Latifa Hanafi, Laura Braun Parvez, Laure Champion, Laure Croze, Laure Eprinchard, Laure Patrier, Laurence Nicolet, Laurence Vrigneaud, Laurent Duflot, Leandre Mackaya, Leila Chenine, Leon Odry, Lili Taghipour Tamiji, Lilia Antri Bouzar, Liliane Ngango Nga Messi, Lionel Le Mouellic, Lise Mandart, Lise Weis, Lise Marie Pouteau, Lora Georgieva, Lorita Vitanova, Lotfi Chalabi, Luc Delvallez, Luc Fromentin, Luc Marty, Luc Monjot, Luciana Spataru, Lucie Bessenay, Lucie Boissinot, Lucie Wajsbrot, Lucien Rakoff, Ludivine Lebourg, Lydie Perez, Lyliane Lafage, Lynda Azzouz, Madeleine Dumoulin, Messaoud Ouziala, Maan Joseph, Mabrouk Brahimi, Maeva Wong Fat, Magalie Fort, Magued Nakhla, Mahdi Abtahi, Mahen Albadawy, Mahmoud Alouach, Mahmoud Mezghani, Maite Daroux, Maklouf Boukelmoune, Malek Dhib, Malik Touam, Malina Dubau, Mamadou Balde, Man Nguyen Khoa, Manfred Ismer, Manolie Mehdi, Manon Laforet, Marc Bouiller, Marc Eugene, Marc Fila, Marc Hazzan, Marc Kribs, Marc Ladriere, Marc Lebot, Marc Padilla, Marc Souid, Marcel Marraoui, Maren Burbach, Maria Manescu, Maria Eugenia Noguera Gonzalez, Mariana Revenco, Marianne Terrasse, Marie Essi, Marie Alice Macher, Marie Beatrice Nogier, Marie Cecile Cazin, Marie Christine Schweitzer Camoin, Marie Christine Thouret, Marie Claude Hannaert, Marie France Servel, Marie Helene Chabannier, Marie Jeanne Coudert Krier, Marie Noelle Catoliquot, Marie Paule Guillodo, Marie Sophie Gavard, Marie Xaviere Vairon Codaccioni, Marina Rabec, Marine Freist, Marion Gauthier, Marion Lemaire, Marion Mehrenberger, Marion Venot, Marios Pongas, Marlene Beaubrun Diant, Martial Levannier, Martine Bertaux, Mathieu Jablonski, Mathieu Sacquepee, Mathilde Dargelos, Mathilde Lemoine, Mathilde Tamain, Matthieu Monge, Matthieu Reberolle, Maud Cousin, Maud Francois, Maurice Baron, Maxime Hoffmann, Maxime Ingwiller, Maxime Touzot, Mederick Mohajer, Mehadji Maaz, Melanie Hanoy, Melanie Marroc, Melodie Cuny, Menno Van Der Straaten, Mf. Serveaux, Michel Basteri, Michel Fen Chong, Michel Hecht, Michel Massad, Michel Normand, Michel Olmer, Michel Tolani, Michel Tsimaratos, Michele Hemery, Michele Kessler, Miguel Esposito, Milad Shenouda, Mimi Kareche, Mina Khalili, Mirella Diaconita, Mohamad Khair Rifard, Mohamed Aladib, Mohamed Belmouaz, Mohamed Brahim, Mohamed Diouani, Mohamed Fodil Cherif, Mohamed Jamali, Mohamed Maghlaoua, Mohamed Meddeb, Mohamed Ramdane, Mohamed Rifaat, Mohamed Sharifull Islam, Mohamed Adnan Abbade, Mokhtar Amrandi, Mokhtar Chawki, Monica Ciobotaru, Monica Indrieis, Monique Chanas, Monique Hoarau, Monzer Tomeh, Moufida Bellou, Mouloud Bouzernidj, Mounia Ammor, Mounir Guergour, Mountassir Benzakour, Mourad Hachicha, Moussa Coulibaly, Mustafa Smati, Mustapha Al Morabiti, Mustapha Amirou, Myriam Isnard, Myriam Pastural, Myriam Pujo, Nourredine Boumendjel, Nabil Majbri, Nabila Goumri, Nadege Mingat, Nader Bassilios, Nadia Kerkeni, Nadia Sedrati, Nadia Soltani, Nadine Maroun, Nadine Neyrat, Nahn Luang, Najeh El Esper, Naji Ammar, Nasredine Ghali, Nasser Hamdini, Natacha Noel, Natacha Potelune, Nathalie Maisonneuve, Nathalie Pertuiset, Nathalie Raynal, Nathalie Vittoz, Nazim Terki, Nelly Castin, Nestor Nankeu, Nicolas Bouvier, Nicolas Keller, Nicolas Legros, Nicolas Peters, Nicolas Quirin, Nicole Lefrancois, Nicole Monnier, Nicole Rance, Niels Bruckmann, Noel Mertens, Nolwenn Lorcy, Olivia Gilbert, Olivier Coldefy, Olivier Drouineau, Olivier Dunand, Olivier Fritz, Olivier Imhoff, Olivier Kourilsky, Olivier Lavelle, Olivier Papin, Olivier Roques, Ophelie Le Maner, Oussamah Fikri Benbrahim, Pablo Antonio Erina Torres, Pablo Antonio Urena Torres, Paolo Malvezzi, Pascal Bindi, Pascal Cluzel, Pascal Fontanier, Pascal Wheatley, Pascale Depraetre, Pascale Dubosq, Pascale Halin, Pascale Sebahoun, Pascale Siohan, Pascale Testevuide, Patrice Deteix, Patrice Nolen, Patricia Hue, Patricia Lemarchand, Patrick Donnadieu, Patrick Fievet, Patrick Fohrer, Patrick Francais, Patrick Giraud, Patrick Hallonet, Patrick Henri, Patrick Michaut, Patrick Niaudet, Patrick Pauly, Patrick Thomas, Patrik Deleaval, Paul Finielz, Paul Stroumza, Paule Hardy Yverneau, Pauline Caillard, Pedro Palacin, Perrine Aubertin, Philippe Attias, Philippe Chauveau, Philippe Coindre, Philippe Coste, Philippe Dubot, Philippe Fournier, Philippe Hiernaux, Philippe Jousset, Philippe Lan Yue Wah, Philippe Lang, Philippe Le Cacheux, Philippe Martin Dupont, Philippe Michel, Philippe Mirgaine, Philippe Moriniere, Philippe Nicoud, Philippe Rieu, Philippe Rousseau, Philippe Sporer, Philippe Thorel, Philippe Vanhille, Philippe Vigeral, Philippe Zaoui, Pierre Bataille, Pierre Brignon, Pierre Filipozzi, Pierre Housset, Pierre Peyronnet, Pierre Ramperez, Pierre Vautrin, Pierre Alexandre Michel, Pierre Francois Westeel, Pierre Louis Carron, Pierre Yves Durand, Pierrot Parent, Piotr Seniuta, François Kuentz, Rabah Fraoui, Rachel Tetaz, Rachid Amaria, Rachid Bourouma, Rachid Djeffal, Rachida Nebbad, Radia Allal, Radu Dimulescu, Rafaat Boustani, Rafik Mesbah, Raifat Makdassi, Raji Diab, Raluca Puslenghea, Raoul Roura, Rateb Khayat, Raymond Azar, Raymond Frayssinet, Regine Monkam, Rehouni Boulahrouz, Remi Boudet, Renato Demontis, Renaud Gansey, Rene Cuvelier, Renee Schmitt, Reschad Noordally, Reynald Binaut, Rezkallah Latif, Richard Dufresne, Richard Montagnac, Richard Reade, Robert Genin, Robert Novo, Rocsana Fickl, Roger Dufresne, Roger Magnol, Roland Issautier, Romain Mortelette, Ronan Delaval, Ronan Lohro, Roseline M'barga, S. Beau, Clémentine Dupuis, Marie Jacques Vidil, Sabria Hacini, Said Dahmoune, Saliha Lekhal, Salima Ahriz Sakso, Salima Saksi, Salvatore Citarda, Samir Boubenider, Samuel Kassis, Sandra Verhille, Sandrine Genestier, Sandrine Muller, Saoussen Krid, Sarah Richter, Sebastien Delbes, Sebastien Mailliez, Sebastien Veillon, Sébastien Nony, Seddick Benarbia, Severine Beaudreuil, Sidi Ali Benyaghla, Simon Duquennoy, Simona Baluta, Simona Boncila, Sonia Mzoughi, Sonia Ribal, Sophie Acamer, Sophie Chauvet, Sophie Girerd, Sophie Ozenne, Sophie Parahy, Sophie Rubens Duval, Sophie Taque, Soraya Menouer, Soumaya Chargui, Stanislas Bataille, Stephane Barbier, Stephane Billion, Stephane Roueff, Stephane Torner, Stephane Jean Martin, Stephanie Coupel, Sylvie Cloarec, Sylvie Lavaud, Sylvie Leou, T. Chatelet, Tania Onesta, Tassadit Benhabib, Tayeb Bensalem, Theodora Dimulescu, Theophile Sawadogo, Thibault Dolley Hitze, Thierry Baranger, Thierry Boudemaghe, Thierry Hannedouche, Thierry Krummel, Thierry Milcent, Thomas Dervaux, Thomas Guincestre, Thomas Kofman, Thomas Raphael, Thomas Sadreux, Tim Ulinski, Tiphaine Guyon Roger, Tomas Serrato, Tomek Kofman, Tony Wong, Toufik Boubia, Ubald Assogba Gbindoun, Usama Khuzaie, Valerie Caudwell, Valerie Chatelet, Valerie Crougneau, Valerie De Precigout, Valerie Drouillat, Valerie Galantine, Valerie Granveau Hugot, Valerie Leroy, Veronique Boubia, Veronique Falque, Veronique Fournier, Veronique Queron, Veronique Viviani, Victor Gueuttin, Victor Panescu, Victorio Menoyo Calonge, Viet Nguyen, Vincent Allot, Vincent Delattre, Vincent Leduc, Vincent Pradier, Violaine Emal Aglae, Viorica Badulescu, Virginia Molina, Virginie Besson, Virginie Chaigne, Waddah Jaber, Wael Boudi, Wael El Haggan, Wen Qin Guillon, Wided Tabbi Aneni, William Hanf, Wladimir Kohn, Xavier Bellenfant, Xavier Moreau Gaudry, Yahsou Delmas, Yannick Knefati, Yannick Saingra, Yannick Tirolien, Youssef Mann, Yvan Brunak, Yves Dimitrov, Yves Doussy, Yves Tanter, Zaid Benabid, Zaara Soltani, Zacharia Boukerroucha, Zafer Takla, Zana Ramanantsialonina, Zara Dickson, Zead Tubail, Zoe Koochaki Pour, Zohra Boukhalfa, Zohra Jacquot, Agence de la biomédecine [Saint-Denis la Plaine], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Caen Normandie (UNICAEN), Normandie Université (NU), CALYDIAL Vienne, Partenaires INRAE, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Armand Trousseau [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service d'Epidémiologie et Evaluations Cliniques [CHRU Nancy] (Pôle S2R), Centre Universitaire des Maladies Rénales [CHU Caen] (CUMR Caen), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Assistance Publique - Hôpitaux de Marseille (APHM), Service de diabétologie [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Service de Diabétologie [CHU Pitié-Salpétrière], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
0301 basic medicine, Male, medicine.medical_treatment, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Hemodialysis, Home, Disease, MESH: COVID-19 / therapy, registry, Ambulatory Care Facilities, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Aged, 80 and over, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Risk Factors, 80 and over, Prevalence, covid, dialysis, epidemiology, mortality, Aged, Aged, 80 and over, COVID-19, Case-Control Studies, Critical Care, Female, France, Humans, Incidence, Middle Aged, Patient Acuity, Protective Factors, Registries, Renal Dialysis, SARS-CoV-2, Sex Factors, Hypoalbuminemia, MESH: France / epidemiology, education.field_of_study, Incidence (epidemiology), 3. Good health, MESH: COVID-19 / epidemiology, Nephrology, Hemodialysis, medicine.medical_specialty, Population, Lower risk, Article, 03 medical and health sciences, MESH: Sex Factors, Internal medicine, medicine, MESH: SARS-CoV-2, MESH: Renal Dialysis / statistics & numerical data, education, Dialysis, Vascular disease, business.industry, medicine.disease, Former Smoker, MESH: Critical Care / statistics & numerical data, 030104 developmental biology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Home, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, MESH: Hemodialysis, Home / statistics & numerical data
Abstract

The aim of this study was to estimate the incidence of COVID-19 disease in the French national population of dialysis patients, their course of illness and to identify the risk factors associated with mortality. Our study included all patients on dialysis recorded in the French REIN Registry in April 2020. Clinical characteristics at last follow-up and the evolution of COVID-19 illness severity over time were recorded for diagnosed cases (either suspicious clinical symptoms, characteristic signs on the chest scan or a positive reverse transcription polymerase chain reaction) for SARS-CoV-2. A total of 1,621 infected patients were reported on the REIN registry from March 16th, 2020 to May 4th, 2020. Of these, 344 died. The prevalence of COVID-19 patients varied from less than 1% to 10% between regions. The probability of being a case was higher in males, patients with diabetes, those in need of assistance for transfer or treated at a self-care unit. Dialysis at home was associated with a lower probability of being infected as was being a smoker, a former smoker, having an active malignancy, or peripheral vascular disease. Mortality in diagnosed cases (21%) was associated with the same causes as in the general population. Higher age, hypoalbuminemia and the presence of an ischemic heart disease were statistically independently associated with a higher risk of death. Being treated at a selfcare unit was associated with a lower risk. Thus, our study showed a relatively low frequency of COVID-19 among dialysis patients contrary to what might have been assumed., Graphical abstract

Published
2020

7. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial

Author

Julien Hogan, Lucie Bessenay, Sylvie Cloarec, Stéphanie Tellier, Annie Lahoche, Camille Faudeux, Françoise Broux, Aubriana Perez, Djamal Djeddi, Claire Dossier, Isabelle Vrillon, Christine Pietrement, François Nobili, Jérôme Harambat, Anne Jolivot, Emmanuelle Plaisier, Georges Deschênes, S. Guilmin-Crépon, Olivia Boyer, Vincent Audard, Tim Ulinski, Véronique Baudouin, Philippe Eckart, Denis Morin, Anne-Laure Sellier-Leclerc, Gwenaëlle Roussey-Kesler, Vincent Guigonis, Hôpital Robert Debré, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Henri Mondor, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), and Université Sorbonne Paris Cité (USPC)

Subjects
Nephrology, Pediatrics, Nephrotic Syndrome, 030204 cardiovascular system & hematology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, LEHA, law.invention, 0302 clinical medicine, Superiority Trial, Randomized controlled trial, Quality of life, law, Recurrence, hemic and lymphatic diseases, Multicenter Studies as Topic, media_common, Randomized Controlled Trials as Topic, Renal Medicine, Immunoglobulins, Intravenous, Glomerulonephritis, General Medicine, 3. Good health, Treatment Outcome, Medicine, Rituximab, Steroids, medicine.drug, Drug, medicine.medical_specialty, media_common.quotation_subject, nephrology, 03 medical and health sciences, Internal medicine, medicine, Humans, 030203 arthritis & rheumatology, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, business.industry, paediatric nephrology, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.disease, Quality of Life, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neoplasm Recurrence, Local, business, Nephrotic syndrome, glomerulonephritis
Abstract

IntroductionGuidelines for the treatment of steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS) are lacking. Given the substantial impact of SDNS/FRNS on quality of life, strategies aiming to provide long-term remission while minimising treatment side effects are needed. Several studies confirm that rituximab is effective in preventing early relapses in SDNS/FRNS; however, the long-term relapse rate remains high (~70% at 2 years). This trial will assess the association of intravenous immunoglobulins (IVIgs) to rituximab in patients with SDNS/FRNS and inform clinicians on whether IVIg’s immunomodulatory properties can alter the course of the disease and reduce the use of immunosuppressive drugs and their side effects.Methods and analysisWe conduct an open-label multicentre, randomised, parallel group in a 1:1 ratio, controlled, superiority trial to assess the safety and efficacy of a single infusion of rituximab followed by IVIg compared with rituximab alone in childhood-onset FRNS/SDNS. The primary outcome is the occurrence of first relapse within 24 months. Patients are allocated to receive either rituximab alone (375 mg/m²) or rituximab followed by IVIg, which includes an initial Ig dose of 2 g/kg, followed by 1.5 g/kg injections once a month for the following 5 months (maximum dose: 100 g).Ethics and disseminationThe study has been approved by the ethics committee (Comité de Protection des Personnes) of Ouest I and authorised by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé). Results of the primary study and the secondary aims will be disseminated through peer-reviewed publications.Trial registration numberNCT03560011.

Published
2020

8. Microangiopathie thrombotique secondaire à la gemcitabine : peut-on améliorer le dépistage et la prise en charge ?

Author

X. Charmetant, Laurent Juillard, Sandrine Lemoine, Thomas Fournier, Philippe Cassier, Jean-Charles Puthet, and Anne Jolivot

Subjects
Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Nephrology, business.industry, 030220 oncology & carcinogenesis, 030232 urology & nephrology, medicine, business, 3. Good health
Abstract

Resume La microangiopathie thrombotique est une complication rare mais grave du traitement par gemcitabine. Sa prevalence augmente du fait de l’elargissement des indications de cette chimiotherapie. Nous rapportons quatre cas pour lesquels la presentation clinicobiologique est relativement typique, associant hypertension arterielle, proteinurie et augmentation de la creatinine plasmatique. En revanche, la gravite du tableau est variable, necessitant le recours inconstant a une technique d’hemodialyse. Les strategies therapeutiques, outre l’arret systematique de la gemcitabine, ne sont pas consensuelles. Elles ont ete guidees par la gravite du tableau : echanges plasmatiques d’efficacite variable et eculizumab, qui s’est avere efficace lorsqu’il a ete utilise. Il ressort surtout que ce syndrome est compose de signes banals et frequents chez des patients recevant des chimiotherapies, comme les cytopenies et la majoration de la creatinine. Mais ces signes devraient inciter a rechercher d’autres signes plus specifiques, tels qu’une hypertension arterielle, des stigmates d’hemolyse mecanique, une proteinurie ou une hematurie, afin de reconnaitre le plus precocement possible la microangiopathie thrombotique et permettre sa prise en charge rapide, en evitant de nouvelles injections.

Published
2017

9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study

Author

Frank Bridoux, Déborah Chaintreuil, Laurent Juillard, Fitsum Guebre-Egziabher, Lionel Karlin, Florence Sens, Philip Robinson, Anne Jolivot, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National de la Recherche Agronomique (INRA)

Subjects
Male, [SDV]Life Sciences [q-bio], medicine.medical_treatment, DIAGNOSED MULTIPLE-MYELOMA, 030232 urology & nephrology, Pharmacology, Bortezomib, 0302 clinical medicine, Multiple myeloma, Myeloma cast nephropathy, Cast nephropathy, Hazard ratio, Acute kidney injury, Middle Aged, CHEMOTHERAPY, IMPAIRMENT, Combined Modality Therapy, BORTEZOMIB-BASED REGIMENS, 3. Good health, Treatment Outcome, Nephrology, Hemodialysis, chains, REVERSIBILITY, 030220 oncology & carcinogenesis, HIGH CUTOFF HEMODIALYSIS, Female, LIGHT-CHAINS, Free light, medicine.medical_specialty, FREE, Urology, Nephropathy, 03 medical and health sciences, Renal Dialysis, medicine, Humans, Polymethyl Methacrylate, Glucocorticoids, Dialysis, Aged, Retrospective Studies, Chemotherapy, business.industry, Membranes, Artificial, medicine.disease, POLYMETHYLMETHACRYLATE MEMBRANE, Immunoglobulin Light Chains, business, ACUTE-RENAL-FAILURE
Abstract

Background: In patients with cast nephropathy and acute kidney injury (AKI) requiring dialysis, the reduction of serum free light chains (FLC) using chemotherapy and intensive hemodialysis (IHD) with a high cut-off filter may improve renal and patient outcomes. We evaluated the effectiveness of a combination of chemotherapy and IHD with an adsorbent polymethylmethacrylate membrane (IHD-PMMA) on renal recovery and survival. Methods: A single-center retrospective cohort-study was conducted. Between 2007 and 2014, patients with dialysis-dependent acute cast nephropathy treated with chemotherapy and IHD-PMMA were included. Patients had six 6-h hemodialysis sessions a week, until predialysis serum FLC fell below 200 mg/L, for a maximum of 3 weeks. Primary outcomes were renal recovery, defined as dialysis independence, and survival. Results: Seventeen patients were included, all with stage 3 AKI. All received chemotherapy, mostly based on bortezomib and steroids (88%). Twelve patients (71%) achieved renal recovery, usually within 60 days (92%). At 3 months, the overall hematological response rate was 57%; hematological response was maintained for at least 2 years in 86% of responders. At 6, 12, and 24 months, 76, 75, and 62% of patients were alive, respectively. Higher reduction in involved FLC by day 12 (p = 0.022) and day 21 (p = 0.003) was associated with renal recovery. Patients with FLC reduction rate >50% by day 21 experienced a lower mortality (hazard ratio 0.10, 95% CI 0.02–0.63). Conclusion: In patients with dialysis-dependent myeloma cast nephropathy, early FLC removal by IHD-PMMA combined with chemotherapy was associated with high rates of renal recovery and survival.

Published
2017

10. Twin pregnancy in a patient on chronic haemodialysis who already had three pregnancies

Author

Anne Jolivot, Pascaline M Alix, Flora Brunner, Muriel Doret, Laurent Juillard, Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National de la Recherche Agronomique (INRA)

Subjects
Adult, Male, Polyhydramnios, medicine.medical_specialty, Twin pregnancy, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Twins, 030232 urology & nephrology, Gestational Age, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, Renal Dialysis, Intensive care, Diseases in Twins, medicine, Humans, Twin Pregnancy, Dialysis, Respiratory distress, Cesarean Section, business.industry, Obstetrics, Infant, Newborn, Four pregnancies, medicine.disease, 3. Good health, Pregnancy Complications, Nephrology, Pregnancy, Twin, Kidney Failure, Chronic, Gestation, Female, Hemodialysis, business, Chronic hemodialysis, Daily hemodialysis
Abstract

International audience; Pregnancy in women with end-stage renal disease is rare. Multiple pregnancies carry a high risk of complications even in healthy individuals. We report the case of a 36-year-old woman who had four pregnancies while she was on dialysis, including one twin pregnancy. The last pregnancy occurred while in the 14th year of hemodialysis. At 8 weeks of gestation (WG), ultrasonography diagnosed a dichorionic diamniotic twin pregnancy. The frequency of dialysis was increased from 3 to 6 times a week and each session lasted 4 h. At 22 WG, polyhydramnios was diagnosed. At 25 WG, the patient presented respiratory distress and was transferred to intensive care where continuous hemodialysis, non-invasive ventilation, antibiotic and tocolysis were initiated. Because of tocolysis failure, a cesarean section was performed and she delivered male twins. The two newborns weighed 790 and 870 g, respectively. To our knowledge, this is the first report of four pregnancies in hemodialysis including one twin pregnancy. The incidence of pregnancy and a better outcome in patients on hemodialysis has increased in recent years but a tight coordination between nephrologists and obstetricians is essential.

Published
2019

11. Pregnancy Outcomes in French Hemodialysis Patients

Author

Fitsum Guebre-Egziabher, Sylvie Bin, Evelyne Decullier, Anne Jolivot, Marine Panaye, Gabrielle Normand, Laurent Juillard, Muriel Doret, Xiaoli Xu, Sandrine Lemoine, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
trends, Adult, medicine.medical_specialty, dialysis patients, renal-transplant recipients, medicine.medical_treatment, Birth weight, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Gestational Age, 030204 cardiovascular system & hematology, registry, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, Renal Dialysis, Risk Factors, medicine, Birth Weight, Humans, Pregnancy outcomes, Dialysis, Retrospective Studies, Fetus, business.industry, Obstetrics, Cesarean Section, Infant, Newborn, Pregnancy Outcome, Gestational age, cohort, Urology & Nephrology, medicine.disease, Chronic renal insufficiency, 3. Good health, Pregnancy Complications, Catheter, Nephrology, Kidney Failure, Chronic, Female, Hemodialysis, women, France, business
Abstract

Background: Pregnancy in hemodialysis (HD) women is a rare event and often associated with maternal and fetal complications. Scarcity of available data from large cohorts impedes fair medical counseling. Methods: This is a descriptive, retrospective, multi-centric study. Pregnant women on HD during the period from 1985 to 2015 in France were included. The primary outcome was a living infant discharged from hospital, while secondary outcomes included gestational age and birth weight. Results: We identified 100 pregnancies in 84 women on HD, from 41 centers. Chronic HD was initiated during pregnancy for 17.7% (14/79) of patients explaining a 19.8% prevalence of catheter (19/96) and a preserved residual diuresis for 50% of pregnancy (43/86). Seventy-six (89.4%) women performed daily dialysis during the third trimester (6 times per week). Our primary outcome was met for 78% of newborns with a mean gestational age of 33.2 ± 3.9 weeks and a mean birth weight of 1,719 ± 730 g. Conclusions: Our study is one of the largest series of ­pregnancies in HD patients. Despite recent progresses, these pregnancies remain at high risk, reinforcing the need for an early nephrologist-obstetrician skilled team co-management.

Published
2018

12. Prise de benzodiazépines au long cours chez les patients dialysés : une étude descriptive

Author

Carole Paillet, Christine Pivot, Stéphane Sanchez, Florence Sens, Laurent Juillard, Anne Jolivot, and Mathieu Collomb

Subjects
Nephrology
Abstract

Resume Contexte Les troubles anxieux et du sommeil sont frequents chez les patients dialyses et justifient l’utilisation de benzodiazepines. Bien que la duree de traitement ne doive pas exceder 3 mois, beaucoup de patients dialyses utilisent ces molecules au long cours. Les risques d’une telle consommation sont bien connus. Les nephrologues doivent frequemment initier ou poursuivre des traitements par benzodiazepines chez les patients dialyses. Cette prescription est complexe et les etudes relatives aux facteurs associes a leur prise chez cette population particuliere sont pauvres. Objectifs Determiner la prevalence et les facteurs associes a une utilisation au long cours des benzodiazepines chez les patients dialyses, ainsi que la prevalence et les motivations des patients desirant entamer une demarche d’arret suite a l’apport d’une information sur les risques d’une telle consommation. Methodes L’etude a inclus 91 patients dialyses chroniques. Les donnees sont recueillies a partir du dossier medical informatise et au moyen d’entretiens avec les patients. Resultats Au total, 50,5 % des patients (âge moyen : 65,8 ans) consomment une benzodiazepine. La prevalence d’utilisation au long cours est de 78,3 %. Les patients utilisateurs chroniques sont (a) plus âges, (b) moins actifs, (c) plus frequemment atteints de diabete, (d) de depression, (e) plus frequemment en incapacite de marche, (f) moins souvent inscrits sur la liste d’attente de greffe renale, et (g) ont moins souvent beneficie d’une greffe renale prealable. Les doses de benzodiazepines des patients consommateurs au long cours etaient plus elevees que celles des consommateurs sur une courte periode. De plus, 60 % des patients consommateurs chroniques ayant beneficie de l’information desirent entreprendre une demarche d’arret. La constatation d’effets indesirables, l’impression d’inefficacite et la peur de la dependance constituent les motivations les plus souvent identifiees pour justifier le desir d’arret. Conclusions La prevalence de la consommation chronique de benzodiazepines chez les patients dialyses est elevee. L’apport d’une information concernant l’utilisation de ces molecules semble avoir un impact positif sur la demarche d’arret.

Published
2015

13. Grossesse en insuffisance rénale terminale : épidémiologie, prise en charge et pronostic

Author

Fitsum Guebre-Egziabher, Laurent Juillard, Marine Panaye, Anne Jolivot, Sandrine Lemoine, Muriel Doret, and Emmanuel Morelon

Subjects
Pregnancy, medicine.medical_specialty, 030219 obstetrics & reproductive medicine, Eclampsia, business.industry, Obstetrics, medicine.medical_treatment, 030232 urology & nephrology, Intrauterine growth restriction, medicine.disease, 3. Good health, Peritoneal dialysis, 03 medical and health sciences, 0302 clinical medicine, Nephrology, medicine, Hemodialysis, business, Kidney transplantation, Dialysis, Kidney disease
Abstract

Pregnancy in patients presenting end-stage renal disease is rare and there are currently no recommendations for the management of these patients. In hemodialysis patients, reduced fertility and medical reluctance limit the frequency of pregnancies. Although the prognosis has significantly improved, a significant risk for unfavorable maternal (pre-eclampsia, eclampsia) and fetal (pre-term birth, intrauterine growth restriction, still death) outcome still remains. Increasing dialysis dose with the initiation of daily dialysis sessions, early adaptation of medications to limit teratogenicity and management of chronic kidney disease complications (anemia, hypertension) are required. A tight coordination between nephrologists and obstetricians remains the central pillar of the care. In peritoneal dialysis, pregnancy is also possible with modification of the exchange protocol and reducing volumes.

Published
2014

14. Freins à la participation des patients en stade 3 de la maladie rénale chronique à l’éducation thérapeutique proposée en réseau de santé

Author

Sophie Fave, Christelle Maurice, Evelyne Decullier, Maurice Laville, Anne Jolivot, Bruno Duquesne, and Jean-Pierre Desmaris

Subjects
Nephrology, 3. Good health
Abstract

Resume Introduction L’education therapeutique favorise l’acquisition de connaissances et de competences pour le patient vis-a-vis de sa maladie. Certains patients ne souhaitent pas participer aux programmes d’education therapeutique. Comprendre les raisons de cette non-participation aiderait a mieux determiner leurs besoins et permettrait d’adapter l’offre aux patients les moins motives. Patients et methodes Un programme d’education therapeutique dedie aux patients au stade 3 de la maladie renale chronique est propose dans un reseau de sante. L’etude porte sur la participation des patients a ce programme d’education therapeutique. Nous avons recherche les raisons de la non-participation des patients, par questionnaire direct, en le croisant aux donnees des dossiers medicaux. Resultats Parmi 80 patients eligibles et apres avis medical, 66 ont recu une information sur le programme d’education therapeutique. Ainsi, 36 patients ont choisi de participer au programme et 21 ont participe aux ateliers collectifs. Nous n’avons pas retrouve de differences significatives sur le profil medical ou social permettant d’expliquer la non-participation des patients. En revanche, un moindre engagement est observe de la part des patients ayant seulement un suivi bioclinique et ne beneficiant pas de suivis paramedicaux complementaires. Conclusion Pres de la moitie des patients n’ont pas participe au programme d’education therapeutique, prioritairement ceux qui ne beneficiaient pas d’un suivi pluridisciplinaire. L’education therapeutique reste un concept peu connu des patients et necessite une information incitative par les medecins assurant la prise en charge therapeutique.

Published
2014

15. [Gemcitabine-induced thrombotic microangiopathy: Can we improve screening and treatment?]

Author

Xavier, Charmetant, Anne, Jolivot, Thomas, Fournier, Jean-Charles, Puthet, Philippe, Cassier, Sandrine, Lemoine, and Laurent, Juillard

Subjects
Adult, Male, Antimetabolites, Antineoplastic, Plasma Exchange, Thrombotic Microangiopathies, Humans, Female, Middle Aged, Antibodies, Monoclonal, Humanized, Deoxycytidine, Severity of Illness Index, Gemcitabine
Abstract

Thrombotic microangiopathy is a rare but severe complication of treatment with gemcitabine. Its prevalence increases because gemcitabine's indications are growing. We report four cases, which presented with common clinical and biological manifestations, i.e. high blood pressure, proteinuria and increasing plasmatic creatinine level. However, severity was not similar, hemodialysis was inconstant. There is no consensus on treatment for this condition. Stopping gemcitabine is essential. Treatment was dispensed considering the severity of the presentation: plasma exchange therapy of variable outcome, and eculizumab, which was efficient when used. It's important to note that this syndrome includes common and frequent signs in patients receiving chemotherapies. But they must encourage the research of most specific signs, such as hypertension, mechanic hemolysis signs, proteinuria or hematuria, in order to recognize thrombotic microangiopathy as early as possible to treat it precociously, and to prevent additional gemcitabine injections.

Published
2016

16. Paraneoplastic fibrillary glomerulonephritis associated with intrahepatic cholangiocarcinoma: When diagnosis of a rare kidney disease leads to successful hepatic cancer treatment

Author

Valérie Hervieu, Maud Rabeyrin, Jean-Michel Gougon, Pierre-Jean Valette, Jérôme Dumortier, Jean-Yves Scoazec, Anne Jolivot, Gabrielle Normand, Laurent Juillard, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National de la Recherche Agronomique (INRA)

Subjects
Male, Pathology, medicine.medical_specialty, Liver tumor, Paraneoplastic Syndromes, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Cholangiocarcinoma, Diagnosis, Differential, 03 medical and health sciences, 0302 clinical medicine, Glomerulonephritis, Biopsy, medicine, Humans, Intrahepatic Cholangiocarcinoma, Kidney, Hepatology, medicine.diagnostic_test, business.industry, Fibrillary Glomerulonephritis, Gastroenterology, Middle Aged, medicine.disease, 3. Good health, Cancer treatment, medicine.anatomical_structure, Bile Duct Neoplasms, Neoplasm Regression, Spontaneous, 030220 oncology & carcinogenesis, business, Nephrotic syndrome, Kidney disease
Abstract

International audience; A 50-year-old man presented with nephrotic syndrome. Electron microscopy analysis of a kidney biopsy specimen showed fibrillary glomerulonephritis, a rare glomerular disease, while histological analysis of a liver tumor biopsy confirmed an intrahepatic cholangiocarcinoma. The paraneoplastic nature of fibrillary glomerulonephritis is debated but after curative treatment of the hepatic nodule, remission of nephrotic syndrome was confirmed at 6-, 12- and 24-months follow-up. To our knowledge, this is the first description of a paraneoplastic fibrillary glomerulonephritis associated with a cholangiocarcinoma, supported by complete remission achieved following cancer treatment.

Published
2015

17. What about the renal function during childhood of children born from dialysed mothers?

Author

Pauline Abou-Jaoude, Laurence Dubourg, Fitsum Guebre-Egziabher, Justine Bacchetta, Lucie Bessenay, Anne Jolivot, Pierre Cochat, and Adeline Pinçon

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, medicine.medical_treatment, Mothers, Renal function, Blood Pressure, Pilot Projects, Oligohydramnios, Kidney Function Tests, Young Adult, Pregnancy, Renal Dialysis, Risk Factors, Humans, Medicine, Prospective Studies, Transplantation, business.industry, Infant, Newborn, Gestational age, Prognosis, medicine.disease, Pregnancy Complications, Nephrology, Premature birth, Creatinine, Prenatal Exposure Delayed Effects, Gestation, Female, Kidney Diseases, Hemodialysis, beta 2-Microglobulin, business, Follow-Up Studies, Glomerular Filtration Rate
Abstract

Introduction. Pregnancy during dialysis is a high-risk condition which is becoming more and more common. The renal outcome of children born from such pregnancies needs to be investigated since renal development may be affected (i.e. exposure to uraemic toxins, therapies, intermittent haemodynamic changes during sessions, prematurity, growth retardation). Methods. We performed a single-centre prospective global and renal evaluation (inulin clearance or 2009 Schwartz formula in children

Published
2011

18. Are Ghrelin and Leptin Involved in Food Intake and Body Mass Index in Maintenance Hemodialysis?

Author

Philippe Chauveau, Raymond Azar, Jocelyne Drai, Denis Fouque, Denise Mafra, Catherine Michel, and Anne Jolivot

Subjects
Blood Glucose, Leptin, Male, medicine.medical_specialty, Food intake, medicine.medical_treatment, Medicine (miscellaneous), Inflammation, Body Mass Index, Eating, Sex Factors, Equivalent, Renal Dialysis, Internal medicine, medicine, Humans, Aged, Aged, 80 and over, Nutrition and Dietetics, business.industry, digestive, oral, and skin physiology, Age Factors, medicine.disease, Ghrelin, C-Reactive Protein, Endocrinology, Nephrology, Kidney Failure, Chronic, Female, Dietary Proteins, Hemodialysis, Waist Circumference, medicine.symptom, business, Body mass index, hormones, hormone substitutes, and hormone antagonists, Kidney disease
Abstract

Both leptin and ghrelin (in the forms of acyl ghrelin and des-acyl ghrelin) are involved in food intake, and appear to be dysregulated in chronic kidney disease. This study describes plasma leptin, acyl, and des-acyl ghrelin concentrations in relation to protein intake and body mass index (BMI) in hemodialysis (HD) patients.This was a cross-sectional study.This study was conducted during the baseline phase of the French multicenter Influence of a High-Flux Dialyzer on Long-Term Leptin Levels Study.We studied 125 HD patients (aged 72.5+/-11.7 years; 59% males).Blood samples were collected during fasting, and before a regular HD session. Plasma ghrelin and leptin were evaluated. The protein equivalents of total nitrogen appearance and BMI were calculated.Patients demonstrated elevated serum leptin (48.0+/-49.0 ng/mL) and des-acyl ghrelin (646.6+/-489.5 pg/mL) levels, and low acyl ghrelin levels (29.8+/-58.5 pg/mL), according to normal values. Acyl ghrelin was negatively correlated with C-reactive protein (r=-0.34, P.001). The des-acyl to acyl ghrelin ratio was negatively correlated with protein intake, as estimated by normalized Protein Nitrogen Appearance (r=-0.22, P=.01). Serum leptin exhibited its well-described positive correlation with BMI and waist circumference, but the other hormones did not.This study reports high des-acyl ghrelin and leptin levels and low acyl ghrelin levels in HD patients, a finding potentially associated with inflammation and food intake.

Published
2010

19. New Measurements of Energy Expenditure and Physical Activity in Chronic Kidney Disease

Author

Anne Jolivot, Denise Fouque, Christine Cleaud, Walid Arkouche, Patrick Deleaval, Severine Rognon, Marie-Jo Perrot, Daniel Teta, Denise Mafra, and Muriel Thevenet

Subjects
medicine.medical_specialty, Nutrition and Dietetics, business.industry, Nutritional Requirements, Physical activity, Medicine (miscellaneous), Doubly labeled water, medicine.disease, Dialysis patients, Clinical Practice, Nutrition Assessment, Energy expenditure, Predictive Value of Tests, Nephrology, medicine, Humans, Kidney Failure, Chronic, Resting energy expenditure, Exercise physiology, Energy Metabolism, Intensive care medicine, business, Exercise, human activities, Kidney disease
Abstract

The accurate estimation of total daily energy expenditure (TEE) in chronic kidney patients is essential to allow the provision of nutritional requirements; however, it remains a challenge to collect actual physical activity and resting energy expenditure in maintenance dialysis patients. The direct measurement of TEE by direct calorimetry or doubly labeled water cannot be used easily so that, in clinical practice, TEE is usually estimated from resting energy expenditure and physical activity. Prediction equations may also be used to estimate resting energy expenditure; however, their use has been poorly documented in dialysis patients. Recently, a new system called SenseWear Armband (BodyMedia, Pittsburgh, PA) was developed to assess TEE, but so far no data have been published in chronic kidney disease patients. The aim of this review is to describe new measurements of energy expenditure and physical activity in chronic kidney disease patients.

Published
2009

20. Parathormone et maladie rénale chronique

Author

Anne Jolivot, Jean-Claude Souberbielle, Anne Charrié, Justine Bacchetta, Fitsum Guebre, Denis Fouque, and Cécile Chauvet

Subjects
Nephrology, endocrine system, medicine.medical_specialty, Peptide fragment, Bone disease, business.industry, Parathyroid hormone, medicine.disease, Bioinformatics, Organ damage, Endocrinology, Internal medicine, medicine, Renal bone disease, business, hormones, hormone substitutes, and hormone antagonists, Bone biopsy, Kidney disease
Abstract

The serum parathyroid hormone (PTH) rises in chronic kidney disease (CKD) and induces renal bone disease as well as other organ damage. The bone disease guidelines were released by the K-DOQI in 2003 in order to help physicians to improve bone management at all different CKD stages. However, many different PTH commercial assays are available today and some questions are raised concerning the interpretation, the validity and the practical choice of these different measurements. After reviewing PTH biosynthesis and metabolism, we will describe the regulation of different PTH fragments (particularly 1-84 and 7-84) and the various types of PTH assays. In compromised clinical situations, bone biopsy still remains the golden standard assessment of bone disease, and it will be helpful to clarify the interest of new 3rd generation PTH measurements. At present, we do not dispose of valid therapeutic recommendations using 3rd generation tests, as well as the relevance of the ratio PTH 1-84/7-84.

Published
2007

21. [Long-term benzodiazepine use among dialysis patient: A descriptive study]

Author

Mathieu, Collomb, Florence, Sens, Stéphane, Sanchez, Anne, Jolivot, Christine, Pivot, Laurent, Juillard, and Carole, Paillet

Subjects
Adult, Aged, 80 and over, Male, Sleep Wake Disorders, Benzodiazepines, Young Adult, Renal Dialysis, Humans, Female, Middle Aged, Anxiety Disorders, Aged
Abstract

Dialysis patients frequently have anxiety and sleeping disorders and that explains a benzodiazepine treatment. A significant proportion of dialysis patients are long-term users even though it is not recommended to take benzodiazepine for more than 3 months. Risks of such a use are well identified. Nephrologists frequently have to prescribe benzodiazepines. This prescription is complex and there are few studies regarding the factors of benzodiazepine use among this population.To determine the prevalence and the factors related to a long-term benzodiazepine use by dialysis patients. To determine the prevalence and the motivation of patients to stop taking medication among the long-term users who got information about the risk of such a use.The study includes 91 dialysis chronic patients. Their characteristics were collected from medical records and interviews with the patients.The average age of patients is 65,8 years. In all, 50.5% take benzodiazepines. Among benzodiazepine users, the prevalence of long-term use is 78.3%. Long-term benzodiazepine users (a) are older, (b) less active, (c) frequently diabetic, (d) depressive, (e) unable to walk, (f) less often registered on the kidney transplant waiting list, and (g) had less kidney transplant previously. Benzodiazepine doses of long-term users were higher than the doses of short-term users. Moreover, 60% of patients who are chronic users want to take action and stop the treatment. Observation of side effects, impression of ineffectiveness and fear of addiction are the most identified motivation to stop treatment.The prevalence of benzodiazepine chronic use by dialysis patients is high. Giving information to the patient about the use of these molecules seems to have a positive impact on the decision to stop.

Published
2014

22. [Pregnancies in hemodialysis and in patients with end-stage chronic kidney disease : epidemiology, management and prognosis]

Author

Marine, Panaye, Anne, Jolivot, Sandrine, Lemoine, Fitsum, Guebre-Egziabher, Muriel, Doret, Emmanuel, Morelon, and Laurent, Juillard

Subjects
Pregnancy Complications, Fertility, Reproductive Techniques, Assisted, Pregnancy, Renal Dialysis, Humans, Kidney Failure, Chronic, Female, Prognosis
Abstract

Pregnancy in patients presenting end-stage renal disease is rare and there are currently no recommendations for the management of these patients. In hemodialysis patients, reduced fertility and medical reluctance limit the frequency of pregnancies. Although the prognosis has significantly improved, a significant risk for unfavorable maternal (pre-eclampsia, eclampsia) and fetal (pre-term birth, intrauterine growth restriction, still death) outcome still remains. Increasing dialysis dose with the initiation of daily dialysis sessions, early adaptation of medications to limit teratogenicity and management of chronic kidney disease complications (anemia, hypertension) are required. A tight coordination between nephrologists and obstetricians remains the central pillar of the care. In peritoneal dialysis, pregnancy is also possible with modification of the exchange protocol and reducing volumes.

Published
2014

23. [Physical activity and chronic kidney disease: an update in 2013?]

Author

Nicolas, Rognant, Éric, Pouliquen, Sophie, Fave, Anne, Jolivot, and Maurice, Laville

Subjects
Evidence-Based Medicine, Cardiovascular Diseases, Practice Guidelines as Topic, Quality of Life, Humans, Health Promotion, Motor Activity, Renal Insufficiency, Chronic
Abstract

The practice of physical activity is now a subject of special attention in public health. Indeed, the expected benefits in terms of cardiovascular morbidity and mortality suggest that all physicians should promote it. However, there are few data on the impact of physical activity on the health of patients with chronic kidney disease before the dialysis stage. This review focuses on the relationship between chronic kidney disease and the practice of physical activity. Different tools to assess the level of physical activity helped to highlight a marked deterioration in physical capacity of patients with chronic kidney disease, including during the earliest stages. Although there is currently no specific recommendations regarding the practice of physical activity in patients with renal impairment, it seems desirable to promote it in an appropriate way, based on what is currently advocated for cardiovascular prevention in the general population.

Published
2013

24. [Reluctance of patients with chronic kidney disease stage 3 to join education programs offered by a health network]

Author

Sophie, Favé, Anne, Jolivot, Jean-Pierre, Desmaris, Christelle, Maurice, Évelyne, Decullier, Bruno, Duquesne, and Maurice, Laville

Subjects
Aged, 80 and over, Male, Middle Aged, Health Surveys, Severity of Illness Index, Patient Education as Topic, Surveys and Questionnaires, Humans, Female, France, Patient Participation, Renal Insufficiency, Chronic, Aged, Follow-Up Studies
Abstract

Therapeutic education helps patients to acquire the knowledge and ability to live with their disease. However, some patients are not willing to take part in a health education program. Identifying the barriers of their non-adherence would help us to determine accurately their effective educational needs and to adapt the program to deliver a better education for less-motivated patients.An education program for chronic kidney disease stage 3 patients was implemented across a health network. The study is based on patient's participation during each step of the program. The reasons for non-participation were collected, via direct survey and cross-referencing with available medical records.From 80 eligible patients, and after medical approval, 66 patients received information about the program. Thirty-six patients elected to participate in program and 21 of them joined a therapeutic education group. We did not find any significant differences in the medical or social profile to determine the characteristics of non-participating patients. We found less program involvement however, with patients complying with biomedical follow-up but who do not benefit from complementary paramedical care.Nearly half of patients did not take part in the therapeutic education program, primarily those who did not benefit from a multidisciplinary team to manage their chronic disease. Therapeutic education remains a less known concept by patients, and requires an informative and encouraging exhortation from practitioners during casual medical care.

Published
2013

25. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial

Author

Catherine Boudray, Gérard Janin, Maud Francois, Michel Rodier, Michel Lievre, Anne-Elisabeth Heng, Claire Pouteil-Noble, Muriel Rabilloud, Emmanuel Villar, Abdallah Guerraoui, Anne Jolivot, Philippe Zaoui, Vincent Lemaître, Eric Alamartine, Gabriel Choukroun, Alvine Bissery, Bernard Branger, Michèle Kessler, Olivier Moranne, Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), and Evaluation et modélisation des effets thérapeutiques

Subjects
Male, Endocrinology, Diabetes and Metabolism, 030232 urology & nephrology, Type 2 diabetes, Hematocrit, Severity of Illness Index, Gastroenterology, Hemoglobins, 0302 clinical medicine, Endocrinology, Risk Factors, Diabetic Nephropathies, medicine.diagnostic_test, Anemia, Middle Aged, 3. Good health, Cardiovascular Diseases, Practice Guidelines as Topic, Disease Progression, Female, France, Drug Monitoring, medicine.drug, medicine.medical_specialty, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], medicine.drug_class, Iron, Renal function, 030209 endocrinology & metabolism, Drug Costs, 03 medical and health sciences, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Renal Insufficiency, Chronic, Erythropoietin, Aged, business.industry, medicine.disease, Erythropoiesis-stimulating agent, Diabetes Mellitus, Type 2, Hematinics, Quality of Life, Physical therapy, business, Kidney disease
Abstract

Correction of anemia in type 2 diabetes (T2DM) patients with chronic kidney disease stages 3-4 may slow the decline of kidney function but may increase cardiovascular risk through higher hematocrit. The NEPHRODIAB2 study was designed to assess efficacy and safety of complete hemoglobin (Hb) normalization in these patients.We randomly assigned 89 T2DM patients with an estimated glomerular filtration rate (eGFR; abbreviated 175 Modification of Diet in Renal Disease formula) of 25 to 60 ml/min per 1.73 m(2) and moderate anemia (Hb, 100-129 g/l) to a target Hb value in subnormal range (110-129g/l, group 1, n=43) or normal range (130-149 g/l, group 2, n=46). The primary end point was eGFR decline after 2 years of follow-up. Secondary end points included iron and erythropoietin dosage, quality of life (Medical Outcomes Study 36-item Short-Form Health Survey scores) and adverse events.Six months after randomization, the mean Hb levels were120 g/l in group 1 and130 g/l in group 2 (P.05 at 6, 12, 18 and 24 months). Blood pressure, 24-h proteinuria and HbA1c did not differ during follow-up (P.05). Two-year declines in eGFR were -8.7±12.2 in group 1 and -5.1±7.8 ml/min per 1.73 m(2) in group 2 (P=.29). Mean weekly use of erythropoietin was 7.8±11.6 μg in group 1 and 30.1±33.6 μg in group 2 (P.0001). There was no significant difference regarding Medical Outcomes Study 36-item Short-Form Health Survey score change or adverse event occurrence.In this trial, normalization of Hb level in T2DM patients with chronic kidney disease was safe but did not significantly slow renal function decline and increased treatment cost due to erythropoietin use.

Published
2011

26. [Parathormone and chronic kidney disease]

Author

Justine, Bacchetta, Anne, Jolivot, Jean-Claude, Souberbielle, Anne, Charrié, Fitsum, Guebre, Cécile, Chauvet, and Denis, Fouque

Subjects
Parathyroid Hormone, Chronic Disease, Humans, Kidney Failure, Chronic, Kidney Diseases, Bone Diseases, Kidney Tubules, Distal, Peptide Fragments
Abstract

The serum parathyroid hormone (PTH) rises in chronic kidney disease (CKD) and induces renal bone disease as well as other organ damage. The bone disease guidelines were released by the K-DOQI in 2003 in order to help physicians to improve bone management at all different CKD stages. However, many different PTH commercial assays are available today and some questions are raised concerning the interpretation, the validity and the practical choice of these different measurements. After reviewing PTH biosynthesis and metabolism, we will describe the regulation of different PTH fragments (particularly 1-84 and 7-84) and the various types of PTH assays. In compromised clinical situations, bone biopsy still remains the golden standard assessment of bone disease, and it will be helpful to clarify the interest of new 3rd generation PTH measurements. At present, we do not dispose of valid therapeutic recommendations using 3rd generation tests, as well as the relevance of the ratio PTH 1-84/7-84.

Published
2006

33. Cardiovascular complications in CKD 5D (2)

Author

Nobuyuki Oyake, Valentina Romano, Amirhossein Davarpanah, Kosmas Pappas, Martin Auinger, Kamil amboch, Andreana De Mauri, Władysław Sułowicz, Rigas Kalaitzidis, Alessandro Amore, Guangyu Bi, Kunisirou Makino, Erhan Tatar, Carlo Ratti, Eirini Stavrinou, Acar Tuzuner, Solenne Pelletier, Paolo Raggi, Stefano Severi, Toshio Shimada, Natascia Miani, Yongxi Chen, Karl Lhotta, Hiroshi Kimura, Alessandro Zuccalà, Sawako Kato, Satoshi Nomura, Fatih Kircelli, Dan Radulescu, Cristina Karohl, Karine Marquis, Rosanna Coppo, Kazuaki Tanabe, Adrian Covic, Botond Csiky, Giulia Magliano, Ozkan Gungor, Mieczysław Pasowicz, Josep Bonet, Irina Florentina Secara, Peter Kotanko, Oktay Oymak, Ted Trajceski, Selcuk Hazinedaroglu, Renée-Claude Loignon, Roberto Albiani, Giovanni Petrillo, Francesco Romeo, Ismail Kocyigit, Ezequiel Rodriguez-Reimundes, Stig Molsted, Doriana Lucaciu, Yukio Yuzawa, Endre Sulyok, Danuta Galicka-Latała, Denis Steckiph, Alina Stefan, Hideyuki Mukai, Ping Zhu, Antonio Santoro, Meltem Sezis Demirci, Mehmet Ozkahya, Guglielmo Bracco, Antonio Sturniolo, Erika Schuh, Gladziewa Ulrich, Marianna Sgueglia, Bulent Erbay, Rossella Domini, Cengiz Utas, Yasuharu Maeda, Roberta Camilla, Kostas C. Siamopoulos, Fabio Grandi, Reyhan Calayoglu, Sule Sengul, Changying Xing, Takahito Ito, Amparo Galan, Atsuhiro Maeda, Juergen Floege, Stephanos Kountouris, Silvia Badarau, Gernot Schilcher, Stephan Thijssen, Henri Carrara, Rui Chen, Melek Karakurt, Dominiki Economidou, Arzu Ensari, Manfred Wallner, Andreas Vychytil, Pavlina Dzekova, Maria Paola Puccinelli, Manuel Heras Benito, Maria Astrid Rodriguez Gomez, Iva Nikorjaková, Xiaonong Chen, Theresa Gross, Nilufer Oguzhan, Eustatio Leanca, Mihai S. Utescu, Chrysostomos Dimitriadis, Kenan Keven, Giovanni B. Forleo, István Wittmann, Ramon Romero, Saki Ito, Tibor Vas, Galina Severova, Anna-Maria Belechri, Mojgan Mortazavi Najafabadi, George Spanos, Marek Kuzniewski, Cristiana Corsi, Richard Larivière, Oliviero Panzetta, Maddalena Brustia, Adrian P. Harrison, Chris Gamboa, Diego Galli, Matthias Koenig, Georgios Efstratiadis, Sophie Ignace, Stefanie M. Bode-Böger, Maria Kapusta, Michael Etter, Nicola Di Daniele, Roberto Bonaudo, Mihaela Oleniuc, Aydin Unal, Gérard M. London, Muge Ozcan, Konstantinos Pliakos, Katarzyna Janda, Ayse Bilgic, Bulent Tokgoz, Usama Elewa, Akira Itoh, Maria Jose Fernandez-Reyes Luis, Ali Mohammad Faizei, Geoffrey Block, Jens Martens-Lobenhoffer, Dimitrios Memmos, Khaled Abouseif, Gulay Asci, Laurent Juillard, Inga Bayh, Seyed Mohamad Saadatnia, Andrew L. Smith, Maho Watanabe, Hitoshi Nakashima, Athina Tatsioni, Gergely Tóth, Ercan Ok, Havva Cilan, Maria Silvia Borzacchi, Robert Owen Wilson, Lada Trajceska, Brandenburg Vincent, Nan Chen, Inge Eidemak, Luis D'Marco Gascón, Ziba Farajzadegan, Nathan W. Levin, Paul Muntner, Marie Marsova, Leonardo Cagnoli, Laura Cañas, Anne Jolivot, Waled Bichari, Laura-Dumitrita Buimistriuc, Paola David, Amir Ahmad Nassiri, Lucile Mercadal, Bogdan Solnica, Charles R. Swanepoel, Elena Buzdugan, Yoshinari Tsuruta, Len A. Usvyat, Mihai Onofriescu, Nurhan Ozdemir, Norihisa Hosokawa, Yaowen Xu, Panagiotis Giamalis, Firoozeh Moinzadeh, Beata Kusnierz-Cabala, Jordi Bonal, Luca Santini, Huseyin Toz, Kenji Ito, Silvia Cipriani, Rebeca Nicolais, Shuhei Miura, Federica Capurro, Jochen G. Raimann, Shunichi Fukuhara, Carlo Navino, Pier Giorgio Bolasco, Michalis Spartalis, Robert Freercks, Noriaki Kurita, Ionut Nistor, Saso Gelev, Rosa Sanchez Hernandez, Asma Abdeljaouad, Efstratios Kasimatis, Paulina Dumnicka, Beatriz Bayés, Ketteler Markus, A. Filella, Daniele Marcelli, Denis Fouque, Kazuhito Takeda, Shahrzad Shahidi, Elena Ferrer, Véronique Couture, Hirotsugu Uchihara, Gjulsen Selim, Béla Melegh, Friedemann Awiszus, Gernot Lingenhel, Feridun Kavuncu, Takao Saito, H. Fessy, Jana Zahálková, Alvaro Molina Ordas, Mohsen Agharazii, Aleksandar Sikole, Reza Asadzadeh, Maurice Laville, Schurgers Leon, Satoru Ogahara, Martino De Leo, Marek Švesták, Gokhan Nergizoglu, Aikaterini Papagianni, Antonio Bellasi, Murat Sipahioglu, Yoshinari Yasuda, Nicolas Rognant, Emanuel Zitt, Juan Jesus Carrero, Vili Amitov, Monir Sadat Hakemi, Yasuhiro Abe, Efthymios Pappas, Sorin Crisan, Maggie Lam, Junichi Makino, Marco Fernàndez, Danuta Fedak, Despina Karasavvidou, Ariana Condor, Brian Rayner, Shoichi Maruyama, E. Ferramosca, Jesper Løvind Andersen, Emiliano Staffolani, and Siren Sezer

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, medicine, Intensive care medicine, business
Published
2011

Catalog

Books, media, physical & digital resources
See catalog results